Bilimsel çalışmalar

Prof. Dr. Aysun Soysal

417 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Clinical and Electrodiagnostic Characteristics of COVID-19-Associated Guillain-Barré Syndrome: A Multicenter Study

    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2026

    DOI 10.1017/cjn.2026.10659 PMID 42788219 Açık erişimli tam metinKaynak: OpenAlex

  2. Significance of Phrenic Nerve Conduction Study in the Electrodiagnosis of Guillain Barré Syndrome

    Journal of the Peripheral Nervous System, 2026

    DOI 10.1111/jns.70131 PMID 42227702 Açık erişimli tam metinKaynak: ORCID

  3. CD8+CD20+ Cytotoxic T Lymphocytes Exhibit Augmented Degranulation and Pro-inflammatory Potential in Multiple Sclerosis

    Biorxiv, 2026

    DOI 10.64898/2026.01.29.702512 Açık erişimli tam metinKaynak: ORCID

  4. Causal effects of multiple sclerosis therapies in left-truncated registry data

    Multiple Sclerosis Journal, 2026

    DOI 10.1177/13524585261459943 PMID 42479470 Açık erişimli tam metinKaynak: ORCID

  5. Differential Associations Between Left Atrial Volume Parameters and Ischemic Stroke Subtypes

    Haseki Tip Bulteni, 2026

    DOI 10.4274/haseki.galenos.2026.70299 Açık erişimli tam metinKaynak: ORCID

  6. Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry

    Journal of Neurology, 2026

    DOI 10.1007/s00415-026-13632-4 PMID 41634506 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  7. Evaluation of Seropositivity Developed Against Specific Antigens of Helicobacter pylori in Neurodegenerative Diseases

    Noropsikiyatri Arsivi, 2026

    DOI 10.29399/npa.29038 PMID 41613025 Açık erişimli tam metinKaynak: ORCID

  8. Hyperintense acute reperfusion marker (HARM) and thrombus analysis in acute ischemic stroke

    Frontiers in Neurology, 2026

    DOI 10.3389/fneur.2026.1723099 PMID 41940303 Açık erişimli tam metinKaynak: ORCID

  9. Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder

    Neurology, 2026

    DOI 10.1212/wnl.0000000000214707 PMID 41785437 Kaynak: ORCID

  10. Predicting disease progression in multiple sclerosis with clinically accessible information and technology

    Journal of Neurology, 2026

    DOI 10.1007/s00415-026-13802-4 PMID 42002655 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  11. Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

    CNS Drugs, 2026

    DOI 10.1007/s40263-026-01287-8 PMID 41935174 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  12. Reduced vagal reserve in benign paroxysmal positional vertigo: preliminary results of a case-control HRV study

    European Archives of Oto Rhino Laryngology, 2026

    DOI 10.1007/s00405-026-10479-3 PMID 42507201 Kaynak: ORCID

  13. Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

    Medrxiv, 2026

    DOI 10.64898/2026.03.09.26347918 Açık erişimli tam metinKaynak: ORCID

  14. Sensory neuronopathy: evaluation of clinical and electrophysiological features, etiology, and treatment responses

    Neuroscience Applied, 2026

    DOI 10.1016/j.nsa.2025.105726 Açık erişimli tam metinKaynak: OpenAlex

  15. Geomagnetic Disturbance and Ultraviolet Exposures Influence Multiple Sclerosis Onset Timing

    Document Server@UHasselt (UHasselt), 2026

    Açık erişimli tam metinKaynak: OpenAlex

  16. Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis

    Brain, 2026

    DOI 10.1093/brain/awag252 PMID 42496160 Açık erişimli tam metinKaynak: OpenAlex

  17. How patients with neuromyelitis optica spectrum disease accumulate disability

    Multiple Sclerosis Journal, 2026

    DOI 10.1177/13524585261489039 PMID 42847346 Açık erişimli tam metinKaynak: OpenAlex

  18. Disease-modifying therapies in managing disability worsening in adult relapsing multiple sclerosis: a population-based longitudinal study using the MSBase registry

    BMC Medicine, 2026

    DOI 10.1186/s12916-026-05365-y Açık erişimli tam metinKaynak: OpenAlex

  19. Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder

    JOURNAL OF NEUROLOGY, 2026

    DOI 10.1212/wnl.00000000002147 Kaynak: YÖK Akademik

  20. Antibodies against SARS-CoV-2 in cerebrospinal fluid: Clinical features and laboratory findings of hospitalized patients with neurologic symptoms in the pandemic era,SARS-CoV-2 elleni antitestek az agygerincvelői folyadékban: neurológiai tünetekkel kórházba került betegek klinikai jellemzői és laboratóriumi leletei a világjárvány idején

    Ideggyogyaszati Szemle, 2025

    DOI 10.18071/isz.77.0136 PMID 40163003 Kaynak: ORCID

  21. CD20+ natural killer cells are polyfunctional, memory-like cells that are enriched in inflammatory disorders

    Journal of Immunology, 2025

    DOI 10.1093/jimmun/vkaf205 PMID 40849886 Açık erişimli tam metinKaynak: ORCID

  22. CD20+ natural killer cells are polyfunctional, memory-like cells that are enriched in inflammatory disorders

    Biorxiv, 2025

    DOI 10.1101/2025.01.09.632131 Açık erişimli tam metinKaynak: ORCID

  23. Clinical Characteristics and Prognostic Clinical Factors of Anti-Gamma-Aminobutyric Acid-B Receptor (Gabab-R) Encephalitis in Turkiye: A Multicenter Study

    Ssrn, 2025

    DOI 10.2139/ssrn.5063432 Kaynak: ORCID

  24. Clinical characteristics and prognostic clinical factors of anti-gamma-aminobutyric acid-B receptor (GABAB-R) encephalitis in Türkiye: a multicenter study

    Neurological Research, 2025

    DOI 10.1080/01616412.2025.2495932 PMID 40314255 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  25. Evaluating the Impact of Heroin Abuse on Cerebral Bioelectrical Activity in Adolescents: A Quantitative Electroencephalography Study

    Neurological Sciences and Neurophysiology, 2025

    DOI 10.4103/nsn.nsn_41_25 Açık erişimli tam metinKaynak: ORCID

  26. First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis

    Neurotherapeutics, 2025

    DOI 10.1016/j.neurot.2025.e00552 PMID 39965993 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  27. Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data

    Npj Digital Medicine, 2025

    DOI 10.1038/s41746-025-01788-8 PMID 40707601 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  28. Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study

    Journal of Neurology Neurosurgery and Psychiatry, 2025

    DOI 10.1136/jnnp-2024-334090 PMID 39231582 8 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  29. Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry

    Therapeutic Advances in Neurological Disorders, 2025

    DOI 10.1177/17562864251399595 PMID 41466847 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  30. Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, 2025

    DOI 10.1001/jamaneurol.2025.0495 PMID 40227706 44 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  31. Vaccination strategies in multiple sclerosis patients with Delphi methodology: A Turkish consensus

    Neurology Asia, 2025

    DOI 10.54029/2025eme Açık erişimli tam metinKaynak: ORCID

  32. Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

    Multiple Sclerosis Journal, 2025

    DOI 10.1177/13524585251349125 PMID 40621862 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  33. Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability

    JAMA Network Open, 2025

    DOI 10.1001/jamanetworkopen.2025.31581 PMID 40952740 7 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  34. ECTRIMS 2025 Paper Poster Session 1 and 2

    Multiple Sclerosis Journal, 2025

    DOI 10.1177/13524585251358344 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  35. AB-290. Effectiveness of intermittent theta burst stimulation as an adjunct to constraint-induced movement therapy in patients with stroke to enhance upper extremity recovery: A randomized controlled study

    Clinical Neurophysiology, 2025

    DOI 10.1016/j.clinph.2025.02.098 Kaynak: OpenAlex

  36. The Relationship Between Stigma Level and Depression, Anxiety and Quality of Life in People with Multiple Sclerosis

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Kaynak: Web of Science

  37. Real-world effectiveness of ocrelizumab in multiple sclerosis: a multi-registry observational cohort study

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Kaynak: Web of Science

  38. Factors Contributing to Fatigue in People with Multiple Sclerosis: A Cross-Sectional Analysis

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Kaynak: Web of Science

  39. Machine Learning-Generated Longitudinal Synthetic International Data in Multiple Sclerosis

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Kaynak: Web of Science

  40. From Data to Diagnosis: Harmonizing RRMS and SPMS Classification via AI Models on Global and National Scales

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Kaynak: Web of Science

  41. FLoRank: Adaptive Structured Personalization in Federated Learning for Predicting Disability Progression in Multiple Sclerosis

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Kaynak: Web of Science

  42. Disease-Modifying Treatment Cessation or Switch Due to Pregnancy Planning in Women with MS: Is It Safe?

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Kaynak: Web of Science

  43. Bayesian network to generate representative longitudinal data in multiple sclerosis

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Kaynak: Web of Science

  44. Cladribine as an exit strategy in people with MS over the age of 50

    MULTIPLE SCLEROSIS JOURNAL, 2025

    1 atıf (Web of Science) Kaynak: Web of Science

  45. Risk of disability progression and therapy escalation in MS patients with spinal cord lesions at first presentation. An MSBase registry study

    MULTIPLE SCLEROSIS JOURNAL, 2025

    1 atıf (Web of Science) Kaynak: Web of Science

  46. Single silent lesions matter: a comprehensive assessment of the prognostic impact of clinically silent MRI lesions in RRMS, and an emulated trial of treatment escalation

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Kaynak: Web of Science

  47. Effectiveness of autologous haematopoietic stem cell transplant in comparison with anti-CD20 therapies in relapsing-remitting multiple sclerosis

    MULTIPLE SCLEROSIS JOURNAL, 2025

    Kaynak: Web of Science

  48. Clinically silent MRI lesions in RRMS: prognostic impact and an emulated trial of disease modifying therapy escalation

    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2025

    DOI 10.1136/jnnp-2025-abn.247 Kaynak: Web of Science

  49. A Case Report of Lafora Disease Associated with NHLRC1 Gene Mutation

    EPILEPSIA, 2025

    Kaynak: Web of Science

  50. Electrodiagnostic methods to verify Guillain‐Barré syndrome subtypes in Istanbul: A prospective multicenter study

    Journal of the Peripheral Nervous System, 2024

    DOI 10.1111/jns.12612 PMID 38291679 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex